Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study
Abstract Background Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), includi...
Gespeichert in:
| Veröffentlicht in: | JNCI : Journal of the National Cancer Institute 2023-05, Vol.115 (5), p.570-577 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 577 |
|---|---|
| container_issue | 5 |
| container_start_page | 570 |
| container_title | JNCI : Journal of the National Cancer Institute |
| container_volume | 115 |
| creator | Majidi, Azam Na, Renhua Jordan, Susan J DeFazio, Anna Obermair, Andreas Friedlander, Michael Grant, Peter Webb, Penelope M |
| description | Abstract
Background
Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), including regular and low-dose aspirin, and 5-year cancer-specific survival after an OC diagnosis.
Methods
The Ovarian cancer Prognosis And Lifestyle study is a prospective population-based cohort of 958 Australian women with OC. Information was gathered through self-completed questionnaires. We classified NSAID use during the year prediagnosis and postdiagnosis as none or occasional ( |
| doi_str_mv | 10.1093/jnci/djac239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10165482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jnci/djac239</oup_id><sourcerecordid>3051824719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-c97ab278756489a0470365b86284706f8265552523fe16b5ef59c7c58653e4973</originalsourceid><addsrcrecordid>eNp9kctrGzEQxkVpadwkt56LoIek0G30fvQSjOkLDA4kOQtZ1joyu5Ir7Rr831fBTmh66FxmYH7zMTMfAO8x-oKRpleb6MLVamMdofoVmGAmUEMw4q_BBCEiG6UkOwHvStmgGpqwt-CECsmYxmwC2lnq-xShjbZb-xJcqeUKpp3NwUbobHQ-wzLmXdjZ7iscHjxcvGze5LSOqYQCp3VyHlpfhn3n4eXiZjr_BG-HcbU_A29a2xV_fsyn4P77t7vZz2a--PFrNp03jjE-NE5LuyRSSS6Y0hYxiajgSyWIqqVoFRGcc8IJbT0WS-5brp10XAlOPdOSnoLrg-52XPZ-5Xwcsu3MNofe5r1JNpiXnRgezDrtDEZYcKZIVbg8KuT0e6ynmD4U57vORp_GYoiUVGJdP1nRj_-gmzTm-shiKOJYEVbBSn0-UC6nUrJvn7fByDw6aB4dNEcHK_7h7wue4SfLKnBxANK4_b_UH-YOpHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3051824719</pqid></control><display><type>article</type><title>Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Majidi, Azam ; Na, Renhua ; Jordan, Susan J ; DeFazio, Anna ; Obermair, Andreas ; Friedlander, Michael ; Grant, Peter ; Webb, Penelope M</creator><creatorcontrib>Majidi, Azam ; Na, Renhua ; Jordan, Susan J ; DeFazio, Anna ; Obermair, Andreas ; Friedlander, Michael ; Grant, Peter ; Webb, Penelope M</creatorcontrib><description>Abstract
Background
Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), including regular and low-dose aspirin, and 5-year cancer-specific survival after an OC diagnosis.
Methods
The Ovarian cancer Prognosis And Lifestyle study is a prospective population-based cohort of 958 Australian women with OC. Information was gathered through self-completed questionnaires. We classified NSAID use during the year prediagnosis and postdiagnosis as none or occasional (<1 d/wk), infrequent (1-3 d/wk), and frequent (≥4 d/wk) use. We measured survival from the start of primary treatment: surgery or neoadjuvant chemotherapy for analyses of prediagnosis use, or 12 months after starting treatment (postdiagnosis use) until the earliest of date of death from OC (other deaths were censored) or last follow-up to 5 years. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) and applied inverse-probability of treatment weighting to minimize confounding. We also calculated restricted mean survival times.
Results
Compared with nonusers and infrequent users, we observed better survival associated with frequent NSAID use prediagnosis (HR = 0.73, 95% CI = 0.55 to 0.97) or postdiagnosis (HR = 0.65, 95% CI = 0.45 to 0.94). Estimates were similar for aspirin and nonaspirin NSAIDs, new and continuous users and in weighted models. These differences would translate to a 2.5-month increase in mean survival by 5 years postdiagnosis. There was no association with acetaminophen.
Conclusions
Our findings confirm a previous study suggesting NSAID use might improve OC survival.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/djac239</identifier><identifier>PMID: 36744914</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Acetaminophen ; Acetaminophen - therapeutic use ; Analgesics ; Analgesics - therapeutic use ; Anti-inflammatory agents ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Aspirin ; Aspirin - therapeutic use ; Australia - epidemiology ; Cancer ; Chemotherapy ; Confidence intervals ; Female ; Humans ; Medical prognosis ; Nonsteroidal anti-inflammatory drugs ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Population studies ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Risk Factors ; Self completed questionnaires ; Statistical analysis ; Survival</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2023-05, Vol.115 (5), p.570-577</ispartof><rights>The Author(s) 2023. Published by Oxford University Press. 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-c97ab278756489a0470365b86284706f8265552523fe16b5ef59c7c58653e4973</citedby><cites>FETCH-LOGICAL-c445t-c97ab278756489a0470365b86284706f8265552523fe16b5ef59c7c58653e4973</cites><orcidid>0000-0003-2815-3060 ; 0000-0002-4566-1414 ; 0000-0003-0057-4744 ; 0000-0003-0733-5930 ; 0000-0003-1350-7508 ; 0000-0002-9830-8462 ; 0000-0003-3090-795X ; 0000-0003-2199-1117</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36744914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Majidi, Azam</creatorcontrib><creatorcontrib>Na, Renhua</creatorcontrib><creatorcontrib>Jordan, Susan J</creatorcontrib><creatorcontrib>DeFazio, Anna</creatorcontrib><creatorcontrib>Obermair, Andreas</creatorcontrib><creatorcontrib>Friedlander, Michael</creatorcontrib><creatorcontrib>Grant, Peter</creatorcontrib><creatorcontrib>Webb, Penelope M</creatorcontrib><title>Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>Abstract
Background
Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), including regular and low-dose aspirin, and 5-year cancer-specific survival after an OC diagnosis.
Methods
The Ovarian cancer Prognosis And Lifestyle study is a prospective population-based cohort of 958 Australian women with OC. Information was gathered through self-completed questionnaires. We classified NSAID use during the year prediagnosis and postdiagnosis as none or occasional (<1 d/wk), infrequent (1-3 d/wk), and frequent (≥4 d/wk) use. We measured survival from the start of primary treatment: surgery or neoadjuvant chemotherapy for analyses of prediagnosis use, or 12 months after starting treatment (postdiagnosis use) until the earliest of date of death from OC (other deaths were censored) or last follow-up to 5 years. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) and applied inverse-probability of treatment weighting to minimize confounding. We also calculated restricted mean survival times.
Results
Compared with nonusers and infrequent users, we observed better survival associated with frequent NSAID use prediagnosis (HR = 0.73, 95% CI = 0.55 to 0.97) or postdiagnosis (HR = 0.65, 95% CI = 0.45 to 0.94). Estimates were similar for aspirin and nonaspirin NSAIDs, new and continuous users and in weighted models. These differences would translate to a 2.5-month increase in mean survival by 5 years postdiagnosis. There was no association with acetaminophen.
Conclusions
Our findings confirm a previous study suggesting NSAID use might improve OC survival.</description><subject>Acetaminophen</subject><subject>Acetaminophen - therapeutic use</subject><subject>Analgesics</subject><subject>Analgesics - therapeutic use</subject><subject>Anti-inflammatory agents</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Aspirin</subject><subject>Aspirin - therapeutic use</subject><subject>Australia - epidemiology</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>Female</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Population studies</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Self completed questionnaires</subject><subject>Statistical analysis</subject><subject>Survival</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kctrGzEQxkVpadwkt56LoIek0G30fvQSjOkLDA4kOQtZ1joyu5Ir7Rr831fBTmh66FxmYH7zMTMfAO8x-oKRpleb6MLVamMdofoVmGAmUEMw4q_BBCEiG6UkOwHvStmgGpqwt-CECsmYxmwC2lnq-xShjbZb-xJcqeUKpp3NwUbobHQ-wzLmXdjZ7iscHjxcvGze5LSOqYQCp3VyHlpfhn3n4eXiZjr_BG-HcbU_A29a2xV_fsyn4P77t7vZz2a--PFrNp03jjE-NE5LuyRSSS6Y0hYxiajgSyWIqqVoFRGcc8IJbT0WS-5brp10XAlOPdOSnoLrg-52XPZ-5Xwcsu3MNofe5r1JNpiXnRgezDrtDEZYcKZIVbg8KuT0e6ynmD4U57vORp_GYoiUVGJdP1nRj_-gmzTm-shiKOJYEVbBSn0-UC6nUrJvn7fByDw6aB4dNEcHK_7h7wue4SfLKnBxANK4_b_UH-YOpHQ</recordid><startdate>20230508</startdate><enddate>20230508</enddate><creator>Majidi, Azam</creator><creator>Na, Renhua</creator><creator>Jordan, Susan J</creator><creator>DeFazio, Anna</creator><creator>Obermair, Andreas</creator><creator>Friedlander, Michael</creator><creator>Grant, Peter</creator><creator>Webb, Penelope M</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2815-3060</orcidid><orcidid>https://orcid.org/0000-0002-4566-1414</orcidid><orcidid>https://orcid.org/0000-0003-0057-4744</orcidid><orcidid>https://orcid.org/0000-0003-0733-5930</orcidid><orcidid>https://orcid.org/0000-0003-1350-7508</orcidid><orcidid>https://orcid.org/0000-0002-9830-8462</orcidid><orcidid>https://orcid.org/0000-0003-3090-795X</orcidid><orcidid>https://orcid.org/0000-0003-2199-1117</orcidid></search><sort><creationdate>20230508</creationdate><title>Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study</title><author>Majidi, Azam ; Na, Renhua ; Jordan, Susan J ; DeFazio, Anna ; Obermair, Andreas ; Friedlander, Michael ; Grant, Peter ; Webb, Penelope M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-c97ab278756489a0470365b86284706f8265552523fe16b5ef59c7c58653e4973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acetaminophen</topic><topic>Acetaminophen - therapeutic use</topic><topic>Analgesics</topic><topic>Analgesics - therapeutic use</topic><topic>Anti-inflammatory agents</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Aspirin</topic><topic>Aspirin - therapeutic use</topic><topic>Australia - epidemiology</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>Female</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Population studies</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Self completed questionnaires</topic><topic>Statistical analysis</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Majidi, Azam</creatorcontrib><creatorcontrib>Na, Renhua</creatorcontrib><creatorcontrib>Jordan, Susan J</creatorcontrib><creatorcontrib>DeFazio, Anna</creatorcontrib><creatorcontrib>Obermair, Andreas</creatorcontrib><creatorcontrib>Friedlander, Michael</creatorcontrib><creatorcontrib>Grant, Peter</creatorcontrib><creatorcontrib>Webb, Penelope M</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Majidi, Azam</au><au>Na, Renhua</au><au>Jordan, Susan J</au><au>DeFazio, Anna</au><au>Obermair, Andreas</au><au>Friedlander, Michael</au><au>Grant, Peter</au><au>Webb, Penelope M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>2023-05-08</date><risdate>2023</risdate><volume>115</volume><issue>5</issue><spage>570</spage><epage>577</epage><pages>570-577</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><abstract>Abstract
Background
Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), including regular and low-dose aspirin, and 5-year cancer-specific survival after an OC diagnosis.
Methods
The Ovarian cancer Prognosis And Lifestyle study is a prospective population-based cohort of 958 Australian women with OC. Information was gathered through self-completed questionnaires. We classified NSAID use during the year prediagnosis and postdiagnosis as none or occasional (<1 d/wk), infrequent (1-3 d/wk), and frequent (≥4 d/wk) use. We measured survival from the start of primary treatment: surgery or neoadjuvant chemotherapy for analyses of prediagnosis use, or 12 months after starting treatment (postdiagnosis use) until the earliest of date of death from OC (other deaths were censored) or last follow-up to 5 years. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) and applied inverse-probability of treatment weighting to minimize confounding. We also calculated restricted mean survival times.
Results
Compared with nonusers and infrequent users, we observed better survival associated with frequent NSAID use prediagnosis (HR = 0.73, 95% CI = 0.55 to 0.97) or postdiagnosis (HR = 0.65, 95% CI = 0.45 to 0.94). Estimates were similar for aspirin and nonaspirin NSAIDs, new and continuous users and in weighted models. These differences would translate to a 2.5-month increase in mean survival by 5 years postdiagnosis. There was no association with acetaminophen.
Conclusions
Our findings confirm a previous study suggesting NSAID use might improve OC survival.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>36744914</pmid><doi>10.1093/jnci/djac239</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2815-3060</orcidid><orcidid>https://orcid.org/0000-0002-4566-1414</orcidid><orcidid>https://orcid.org/0000-0003-0057-4744</orcidid><orcidid>https://orcid.org/0000-0003-0733-5930</orcidid><orcidid>https://orcid.org/0000-0003-1350-7508</orcidid><orcidid>https://orcid.org/0000-0002-9830-8462</orcidid><orcidid>https://orcid.org/0000-0003-3090-795X</orcidid><orcidid>https://orcid.org/0000-0003-2199-1117</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8874 |
| ispartof | JNCI : Journal of the National Cancer Institute, 2023-05, Vol.115 (5), p.570-577 |
| issn | 0027-8874 1460-2105 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10165482 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acetaminophen Acetaminophen - therapeutic use Analgesics Analgesics - therapeutic use Anti-inflammatory agents Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Aspirin Aspirin - therapeutic use Australia - epidemiology Cancer Chemotherapy Confidence intervals Female Humans Medical prognosis Nonsteroidal anti-inflammatory drugs Ovarian cancer Ovarian Neoplasms - drug therapy Population studies Prognosis Proportional Hazards Models Prospective Studies Risk Factors Self completed questionnaires Statistical analysis Survival |
| title | Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A29%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Common%20analgesics%20and%20ovarian%20cancer%20survival:%20the%20Ovarian%20cancer%20Prognosis%20And%20Lifestyle%20(OPAL)%20Study&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Majidi,%20Azam&rft.date=2023-05-08&rft.volume=115&rft.issue=5&rft.spage=570&rft.epage=577&rft.pages=570-577&rft.issn=0027-8874&rft.eissn=1460-2105&rft_id=info:doi/10.1093/jnci/djac239&rft_dat=%3Cproquest_pubme%3E3051824719%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3051824719&rft_id=info:pmid/36744914&rft_oup_id=10.1093/jnci/djac239&rfr_iscdi=true |